Panel on Clinical Practices for Treatment of HIV Infection

[1]  M. Hirsch,et al.  Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. , 2000, JAMA.

[2]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[3]  C. Sabin,et al.  Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. , 1999, AIDS.

[4]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.

[5]  J. Overbaugh,et al.  Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. , 1996, AIDS research and human retroviruses.

[6]  Y. Cao,et al.  HIV-1 drug resistance in newly infected individuals. , 1999, JAMA.

[7]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[8]  D. Richman,et al.  Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy , 1995, Annals of Internal Medicine.

[9]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[10]  C. Jaspers,et al.  Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy , 1999, The Lancet.

[11]  A. Mocroft,et al.  Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection , 1999, The Lancet.

[12]  Richard A. Loftus,et al.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.

[13]  J. McCune,et al.  Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1 , 1998, Nature Medicine.

[14]  T. Chun,et al.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J L Sullivan,et al.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1996, The New England journal of medicine.

[16]  Amalio Telenti,et al.  CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) , 1998, The Lancet.

[17]  J. Kahn,et al.  Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. , 1998, The New England journal of medicine.

[18]  M. Augenbraun,et al.  Antiretroviral therapy for pregnant women. , 1997, American journal of obstetrics and gynecology.

[19]  C. Tamalet,et al.  Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. , 1997, The Journal of infectious diseases.

[20]  J. Ragnaud,et al.  Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. , 1999, The Journal of infectious diseases.

[21]  R. Pomerantz,et al.  Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. , 1999, Journal of human virology.

[22]  E A Emini,et al.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.

[23]  R. Sperling,et al.  Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. , 1998, The Journal of infectious diseases.

[24]  Rob J. De Boer,et al.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation , 1998, Nature Medicine.

[25]  M. Niu,et al.  Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. , 1993, The Journal of infectious diseases.

[26]  R Rode,et al.  Ritonavir and saquinavir combination therapy for the treatment of HIV infection. , 1999, AIDS.

[27]  L. Kalish,et al.  Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[28]  S. Mallal,et al.  Comparison of antiviral response with abacavir/combivir to indinavir/combivir in therapy naive adults at 48 weeks (CNA3005) , 1999 .

[29]  Richard D Moore,et al.  Lack of sex difference in CD4 to HIV-1 RNA viral load ratio , 1999, The Lancet.

[30]  Robert Shafer,et al.  HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed , 1999, Annals of Internal Medicine.

[31]  D S Stein,et al.  CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. , 1992, The Journal of infectious diseases.

[32]  J. Margolick,et al.  Sex differences in HIV-1 viral load and progression to AIDS , 1998, The Lancet.

[33]  E. Vittinghoff,et al.  Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. , 1999, The Journal of infectious diseases.

[34]  D. Ho,et al.  Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. , 1999, The Journal of infectious diseases.

[35]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[36]  A. D. Rodrigues,et al.  Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir , 1997, Antimicrobial agents and chemotherapy.

[37]  C. Fox,et al.  Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy , 1998, Nature Medicine.

[38]  J. Gatell,et al.  Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter , 1993 .

[39]  T. Wright,et al.  Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. , 1999, The Journal of infectious diseases.

[40]  J. Beijnen,et al.  The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. , 1999, AIDS.

[41]  J. Mullins,et al.  Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. , 1998, The Journal of infectious diseases.

[42]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[43]  J. Rodman,et al.  A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients. , 1996, The Journal of infectious diseases.

[44]  J. Saurat,et al.  Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[46]  M. Saag,et al.  Predictors of optimal virological response to potent antiretroviral therapy. , 1999, AIDS.

[47]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[48]  K. Holmes,et al.  USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  T. Schacker,et al.  Clinical and Epidemiologic Features of Primary HIV Infection , 1996, Annals of Internal Medicine.

[51]  J. Leonard,et al.  Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir * , 1998, Clinical pharmacology and therapeutics.

[52]  A. Gringeri,et al.  Randomized double‐blind, placebo‐controlled trial of twice‐daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1 , 1994 .

[53]  K. Tashima,et al.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.

[54]  J Leibowitch,et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.

[55]  J. Montaner,et al.  Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. , 1996, The Journal of infectious diseases.

[56]  A. Lazzarin,et al.  Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. , 1999, AIDS.

[57]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[58]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[59]  M. Youle,et al.  Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. , 1999, AIDS.

[60]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.

[61]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[62]  D. Hawkins,et al.  A controlled trial of zidovudine in primary human immunodeficiency virus infection. , 1995, The New England journal of medicine.

[63]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[64]  J. Gatell,et al.  Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double‐blind placebo‐controlled study , 1994, AIDS.

[65]  E. Rosenberg,et al.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection. , 1999, JAMA.

[66]  C. Katlama,et al.  Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy , 1998, Nature Medicine.

[67]  A. Telenti,et al.  The New England Jour nal of Medicine DISCONTINUATION OF PRIMARY PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN HIV-1–INFECTED ADULTS TREATED WITH COMBINATION ANTIRETROVIRAL THERAPY , 2022 .

[68]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[69]  E. Acosta,et al.  Indinavir Concentrations and Antiviral Effect , 1999, Pharmacotherapy.

[70]  L. Kalish,et al.  Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. , 1999, The New England journal of medicine.

[71]  S. Yerly,et al.  Transmission of antiretroviral-drug-resistant HIV-1 variants , 1999, The Lancet.

[72]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[73]  P. Volberding,et al.  Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. , 1999, The Journal of infectious diseases.

[74]  Louis J. Picker,et al.  Changes in thymic function with age and during the treatment of HIV infection , 1998, Nature.

[75]  A. Breckenridge,et al.  The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites , 1996, AIDS.

[76]  C. Sabin,et al.  CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. , 1999, The Journal of infectious diseases.

[77]  R. Grant,et al.  High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. , 1998, The Journal of clinical investigation.

[78]  J. Schapiro,et al.  Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.

[79]  D. Cooper,et al.  Primary HIV infection: host responses and intervention strategies. , 1991, AIDS.

[80]  Calvin Cohen,et al.  Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease , 1998, The Lancet.

[81]  D. Harris,et al.  RISK FACTORS FOR PERINATAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN WOMEN TREATED WITH ZIDOVUDINE , 1999 .